GLP-1 receptor agonists—semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—have become a revenue driver for many aesthetic practices, marketed as weight-loss and body-contouring adjuncts. But the regulatory and legal ground is unstable. FDA shortage designations, state pharmacy board scrutiny, compounding oversight, and the Corporate Practice of Medicine doctrine create real compliance and liability exposure. This page tracks current legal status, sourcing options, and what enforcement looks like—so you can make an informed decision about whether and how to offer these drugs.